Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Operating Income

Operating Income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$117.42M+20.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$169M-18.2%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$38.89M+48.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.64M-25.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$105.96M-1.5%
PVL
Palvella TherapeuticsPVLA
-$14.86M-88.7%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's operating income?
BioCryst Pharmaceuticals (BCRX) reported operating income of -$701.6M in Q1 2026.
How has BioCryst Pharmaceuticals's operating income changed year-over-year?
BioCryst Pharmaceuticals's operating income decreased by 3405.2% year-over-year, from $21.23M to -$701.6M.
What is the long-term trend for BioCryst Pharmaceuticals's operating income?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's operating income has grown at a 17.7% compound annual growth rate (CAGR), from -$177.72M to $340.99M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.